Your browser is no longer supported. Please, upgrade your browser.
Settings
CLDX Celldex Therapeutics, Inc. daily Stock Chart
CLDX [NASD]
Celldex Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.01 Insider Own0.20% Shs Outstand135.00M Perf Week0.36%
Market Cap379.35M Forward P/E- EPS next Y-0.90 Insider Trans0.00% Shs Float135.00M Perf Month-4.10%
Income-121.50M PEG- EPS next Q-0.25 Inst Own54.30% Short Float5.40% Perf Quarter-5.39%
Sales11.20M P/S33.87 EPS this Y3.40% Inst Trans0.21% Short Ratio6.07 Perf Half Y19.07%
Book/sh1.69 P/B1.66 EPS next Y5.30% ROA-34.50% Target Price7.30 Perf Year-17.60%
Cash/sh1.04 P/C2.70 EPS next 5Y- ROE-50.40% 52W Range2.20 - 3.94 Perf YTD-1.06%
Dividend- P/FCF- EPS past 5Y-2.20% ROI-50.10% 52W High-27.79% Beta2.60
Dividend %- Quick Ratio5.90 Sales past 5Y-6.00% Gross Margin- 52W Low29.32% ATR0.11
Employees205 Current Ratio5.90 Sales Q/Q77.30% Oper. Margin- RSI (14)49.42 Volatility3.96% 3.93%
OptionableYes Debt/Eq0.00 EPS Q/Q30.80% Profit Margin- Rel Volume0.73 Prev Close2.81
ShortableYes LT Debt/Eq0.00 EarningsFeb 06 AMC Payout- Avg Volume1.20M Price2.85
Recom2.30 SMA20-1.03% SMA50-1.32% SMA2002.86% Volume630,564 Change1.25%
Aug-01-17Resumed H.C. Wainwright Buy $10
Nov-07-16Initiated Aegis Capital Buy
Mar-08-16Downgrade Jefferies Buy → Hold
Mar-07-16Downgrade Wedbush Outperform → Neutral $4
Mar-07-16Downgrade Leerink Partners Outperform → Mkt Perform
Mar-07-16Downgrade Guggenheim Buy → Neutral
Mar-01-16Initiated H.C. Wainwright Buy $25
Aug-11-15Reiterated ROTH Capital Buy $43 → $39
Aug-11-15Reiterated Oppenheimer Outperform $45 → $42
Aug-11-15Reiterated Brean Capital Buy $35 → $31
Jun-02-15Reiterated WBB Securities Strong Buy $30 → $40
Nov-17-14Reiterated ROTH Capital Buy $40 → $43
Mar-04-14Reiterated Oppenheimer Outperform $40 → $36
Jul-08-13Reiterated Cantor Fitzgerald Buy $16 → $24
Mar-08-13Reiterated Cantor Fitzgerald Buy $13 → $16
Feb-26-13Reiterated Oppenheimer Outperform $10 → $13
Jan-10-13Reiterated Cantor Fitzgerald Buy $9 → $13
Oct-02-12Reiterated Oppenheimer Outperform $6 → $8
Sep-14-12Reiterated Cantor Fitzgerald Buy $7 → $9
Apr-04-12Initiated Cantor Fitzgerald Buy $7
Jan-21-18 11:00AM  3 Growth Stocks That Could Put Shopify's Returns to Shame Motley Fool
Jan-16-18 08:30AM  Will 2018 Be Celldex Therapeutics, Inc.'s Best Year Yet? Motley Fool
Jan-09-18 04:37PM  AbbVie's Upadacitinib Gains Breakthrough Therapy Designation Zacks
10:42AM  Amgen Announces Acceptance of MAA for Evenity in Europe Zacks
Jan-08-18 05:54PM  Ultragenyx Announces Interim Data from Early Stage Study Zacks
Jan-03-18 07:29AM  3 Biotech Stocks to Buy in January Motley Fool
Jan-02-18 08:57AM  4 Reasons to Include Celldex (CLDX) Stock in Your Portfolio Zacks
Dec-29-17 09:55AM  TherapeuticsMD Submits NDA for VMS Candidate, Shares Rise Zacks
Dec-21-17 09:53AM  AbbVie's RA Candidate Meets Endpoints in 3rd Phase III Study Zacks
Dec-20-17 11:25AM  Minerva Initiates Phase III Study on Schizophrenia Candidate Zacks
10:11AM  TherapeuticsMD Falls Despite Acceptance of NDA: Here's Why Zacks
Dec-19-17 12:31PM  ETFs with exposure to Celldex Therapeutics, Inc. : December 19, 2017 Capital Cube
Dec-14-17 10:09AM  Shire's New Formulation of Oncaspar Gets Approval in Europe Zacks
Dec-13-17 06:14PM  Celldex Therapeutics Inc (NASDAQ:CLDX)s Earnings Grew 23%, Is It Enough? Simply Wall St.
09:40AM  Glaxo's Nucala Label Expansion Application Gets FDA Approval Zacks
Dec-10-17 09:31AM  Why Celldex Therapeutics Stock Reversed Course in November Motley Fool
Dec-08-17 12:34PM  ETFs with exposure to Celldex Therapeutics, Inc. : December 8, 2017 Capital Cube
Dec-01-17 05:51PM  Celldex Begins Phase I Trial on Cancer Candidate CDX-1140 Zacks
09:33AM  Cancer Space Update: Pfizer's Bavencio Fails in Phase III Zacks
08:30AM  Report: Exploring Fundamental Drivers Behind Lannett, Oclaro, Antares Pharma, Workday, The Medicines, and Celldex Therapeutics New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Nov-30-17 09:19AM  Better Buy: Ziopharm Oncology Inc. vs. Celldex Therapeutics, Inc. Motley Fool
08:01AM  Celldex Therapeutics Initiates Phase 1 Study of New Product Candidate CDX-1140 in Solid Tumors GlobeNewswire
Nov-29-17 08:44AM  Here's Where Things Went Wrong for Celldex Therapeutics, Inc. in 2017 Motley Fool
Nov-22-17 07:20AM  Featured Company News - Celldex Starts Phase-2 Combination Study of CDX-3379 and Cetuximab in Head and Neck Squamous Cell Carcinoma ACCESSWIRE
Nov-20-17 12:01PM  ETFs with exposure to Celldex Therapeutics, Inc. : November 20, 2017 Capital Cube
09:33AM  Celldex (CLDX) Initiates Phase II Study on Cancer Candidate Zacks
Nov-17-17 08:01AM  Celldex Therapeutics Initiates Phase 2 Combination Study of CDX-3379 and Cetuximab in Head and Neck Squamous Cell Carcinoma GlobeNewswire
Nov-09-17 09:50AM  Celldex Therapeutics, Inc. :CLDX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017 Capital Cube
07:19AM  Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : November 9, 2017 Capital Cube
Nov-08-17 05:46PM  ETFs with exposure to Celldex Therapeutics, Inc. : November 8, 2017 Capital Cube
01:31PM  How to Invest in Biotech Stocks Motley Fool
10:11AM  Celldex (CLDX) Q3 Loss Narrows, Revenues Beat, Shares Up Zacks
08:00AM  Today's Research Reports on Trending Tickers: Celldex Therapeutics and Idera Pharmaceuticals ACCESSWIRE
Nov-07-17 07:08PM  How Much Did Celldex Therapeutics Incs (CLDX) CEO Pocket Last Year? Simply Wall St. +10.08%
01:02PM  Why Celldex Therapeutics Jumped Higher Today Motley Fool
12:36PM  Celldex Therapeutics, Inc.'s Most Important Takeaway From Q3 Isn't a Number Motley Fool
10:00AM  Why Celldex Therapeutics Stock Crumbled in October Motley Fool
08:11AM  Celldex reports 3Q loss Associated Press
08:01AM  Celldex Reports Third Quarter 2017 Results GlobeNewswire
Nov-06-17 09:52AM  Is Celldex Therapeutics Inc (CLDX) Undervalued? Simply Wall St.
Nov-01-17 11:56AM  Celldex (CLDX) to Report Q3 Earnings: What's in the Cards? Zacks
Oct-26-17 11:02AM  Celldex Therapeutics, Inc. Value Analysis (NASDAQ:CLDX) : October 26, 2017 Capital Cube -5.16%
Oct-25-17 08:14AM  Celldex Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CLDX-US : October 25, 2017 Capital Cube
Oct-17-17 06:17PM  Better Buy: Ziopharm Oncology, Inc. vs. Celldex Therapeutics Motley Fool
Oct-06-17 03:13PM  What's Behind Celldex Therapeutics, Inc.'s 16% Rally in September? Motley Fool
Oct-03-17 08:00AM  Celldex Therapeutics Appoints Margo Heath-Chiozzi, M.D., as Senior Vice President, Regulatory Affairs GlobeNewswire
Oct-02-17 03:27PM  How Does Investing In Celldex Therapeutics Inc (CLDX) Impact Your Portfolio? Simply Wall St.
Sep-26-17 10:46AM  ETFs with exposure to Celldex Therapeutics, Inc. : September 26, 2017 Capital Cube -9.33%
08:10AM  Today's Research Reports on Trending Tickers: Celldex Therapeutics and Genocea Biosciences ACCESSWIRE
Sep-25-17 04:20PM  Why Celldex Therapeutics, Inc. Jumped Higher Today Motley Fool +12.78%
08:09AM  Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : September 25, 2017 Capital Cube
Sep-22-17 08:00AM  Celldex Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference GlobeNewswire +8.13%
Sep-21-17 07:47AM  3 Small-Cap Biotech Stocks to Buy This Fall Motley Fool
Sep-12-17 04:01PM  Celldex Announces Departure of Chief Medical Officer GlobeNewswire
Sep-11-17 10:18PM  ETFs with exposure to Celldex Therapeutics, Inc. : September 12, 2017 Capital Cube
Sep-08-17 08:00AM  Today's Research Reports on Trending Tickers: AVEO Pharmaceuticals, Inc. and Celldex Therapeutics, Inc. ACCESSWIRE -5.80%
Aug-31-17 05:44PM  ETFs with exposure to Celldex Therapeutics, Inc. : August 31, 2017 Capital Cube
Aug-29-17 08:35AM  Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : August 29, 2017 Capital Cube
Aug-24-17 10:03PM  3 Top Healthcare Stocks to Buy Now Motley Fool
05:42PM  Celldex Ends Phase II Enrollment for Breast Cancer Candidate Zacks
11:33AM  Celldex Therapeutics, Inc. :CLDX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 Capital Cube
Aug-23-17 09:15AM  Celldex Announces Completion of Enrollment in Phase 2b Study of Glembatumumab Vedotin in Triple Negative Breast Cancer GlobeNewswire
Aug-19-17 12:03PM  3 Top Biotech Stocks Under $10 Motley Fool
Aug-16-17 08:15PM  Celldex Therapeutics, Inc. Value Analysis (NASDAQ:CLDX) : August 17, 2017 Capital Cube
Aug-14-17 09:37AM  3 Beaten-Up Biotech Stocks: Are They Bargains? Motley Fool
08:26AM  Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : August 14, 2017 Capital Cube
02:11AM  Edited Transcript of CLDX earnings conference call or presentation 8-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
Aug-09-17 10:48AM  Celldex (CLDX) Q2 Loss Narrows, Revenues Beat, Shares Up Zacks
08:02AM  Celldex Therapeutics, Inc. Finishes Second Quarter With Plenty of Cash and Clinical Momentum Motley Fool
Aug-08-17 11:55PM  Celldex reports 2Q loss Associated Press
04:01PM  Celldex Reports Second Quarter 2017 Results GlobeNewswire
Aug-04-17 08:22AM  Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : August 4, 2017 Capital Cube
Aug-02-17 11:30AM  Celldex to Report Second Quarter 2017 Financial Results and Host Corporate Update Call GlobeNewswire
09:20AM  What's in the Cards for Celldex (CLDX) this Earnings Season? Zacks
Jul-19-17 06:30AM  Better Buy: Celldex Therapeutics, Inc. vs. Juno Therapeutics Motley Fool
Jul-14-17 07:01PM  Down 14.8%: Is Celldex Therapeutics Stock an Incredible Bargain? Motley Fool
Jun-24-17 11:42AM  3 Stocks That Could Double Your Money Motley Fool
Jun-18-17 02:32PM  3 Stocks with Universal Display-like Return Potential Motley Fool
Jun-16-17 08:01AM  Celldex Therapeutics Announces Additions to the Board of Directors and Senior Management Team GlobeNewswire
Jun-13-17 07:17AM  Why Is Celldex (CLDX) Down 27% Since the Last Earnings Report? Zacks
Jun-12-17 08:42AM  3 Beaten-Up Biotech Stocks: Are They Bargains? Motley Fool
Jun-11-17 09:47AM  3 Stocks That Look Just Like Oracle in 1986 Motley Fool
Jun-07-17 08:00AM  Today's Research Reports on Stocks to Watch: Celldex Therapeutics and Pandora Media Accesswire -5.86%
Jun-06-17 04:53PM  Here's Why Celldex Therapeutics, Inc. Fell Today Motley Fool -12.45%
04:01PM  Celldex Therapeutics to Participate in the Jefferies 2017 Global Healthcare Conference GlobeNewswire
Jun-05-17 04:27PM  Celldex Therapeutics Presents Phase 1 Study of Varlilumab and Opdivo® at 2017 ASCO Annual Meeting GlobeNewswire -5.54%
04:17PM  Here's What Shaved 14% Off Celldex Therapeutics, Inc.'s Stock Price in May Motley Fool
02:08PM  ETFs with exposure to Celldex Therapeutics, Inc. : June 5, 2017 Capital Cube
11:24AM  Celldex Presents Promising Overall Survival Data from Phase 2 Study of Single-agent Glembatumumab Vedotin in Patients with Checkpoint-Refractory Metastatic Melanoma GlobeNewswire
Jun-02-17 09:49AM  Celldex Therapeutics, Inc. :CLDX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017 Capital Cube
Jun-01-17 09:39AM  Celldex Therapeutics, Inc.: The Bear Case from a Bull Motley Fool
May-30-17 12:26PM  George O. Elston Named Chief Executive Officer of 2X Oncology GlobeNewswire
May-26-17 09:31AM  Celldex's Immuno-Oncology Pipeline Continues to Impress Zacks
May-21-17 06:41AM  Better Buy: Celldex Therapeutics, Inc. vs. Agenus Inc. Motley Fool
May-18-17 07:44AM  3 Value Stocks for Bold Investors Motley Fool
May-17-17 05:01PM  Celldex Therapeutics to Present Clinical Results at 2017 ASCO Annual Meeting GlobeNewswire
May-10-17 10:30AM  Celldex (CLDX) Q1 Loss In Line, Revenues Beat, Shares Up Zacks
08:50AM  3 Stocks That Could Double Your Investment Motley Fool
May-09-17 05:41PM  Celldex Therapeutics, Inc.'s Collaboration with Bristol-Myers Squibb Key in First-Quarter Update Motley Fool
05:34PM  Celldex reports 1Q loss Associated Press
Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; and Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer. It also develops earlier stage drug candidates in clinical development, including CDX-1401, an immunotherapeutic for cancer indications; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers. In addition, the company focuses on the discovery and development of antibody-based drugs targeting receptor tyrosine kinases, such as CDX-0158, a humanized monoclonal antibody currently in a Phase 1 dose escalation study in refractory gastrointestinal stromal tumors and other KIT positive tumors; and CDX-3379, a human monoclonal antibody, which has completed a Phase 1b study in patients with solid tumors. Celldex Therapeutics, Inc. has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; University of Southampton; Amgen Inc.; Amgen Fremont; and Seattle Genetics, Inc. The company is headquartered in Hampton, New Jersey.